This is a working overview of GLP-1 analog, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-04-10 and is reviewed periodically as new material appears.
Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide, GLP-1 receptor agonist | Not a small molecule |
| Backbone substitutions | Non-natural residue at position 8, arginine at position 34 | Slows enzymatic cleavage |
| Side chain | C18 fatty diacid with PEG linker | Enables albumin binding |
| Approximate molecular mass | 4114 Da | Varies slightly with salt form |
| Reported half-life | About one week | Longer than native GLP-1 by orders of magnitude |
Reversed-phase high-performance liquid chromatography is widely used to assess purity and to separate the parent peptide from related substances. Mass spectrometry confirms identity and can resolve modifications that differ by a few daltons. Size-exclusion chromatography detects dimers and higher aggregates, which are relevant to both stability and immunogenicity questions. Peptide mapping with enzymatic digestion locates specific modifications along the sequence. Circular dichroism provides a secondary-structure profile, although it gives limited information about local conformational changes.
Quality control for peptide material focuses on identity, purity, content and the profile of impurities. Common degradants include deamidated and oxidised forms, plus aggregates formed during storage or handling. Forced degradation studies under heat, light, acid and peroxide help define which conditions accelerate change and which analytical methods detect it. Limits for individual impurities are set by pharmacopoeial monographs or manufacturer specifications. How much a given impurity affects biological activity is often uncertain, and conclusions may depend on the assay used.
Stability studies examine how temperature, pH, and moisture influence degradation rates over time. In aqueous solution, hydrolysis and deamidation accelerate as pH moves away from mildly acidic conditions. Light exposure and residual metal ions can also trigger oxidation of susceptible residues. Accelerated aging at elevated temperature is used to estimate shelf life, though extrapolation to room temperature carries uncertainty because individual degradation pathways do not always scale predictably.
Lyophilized semaglutide powder is typically held at minus twenty degrees Celsius for long-term storage. At that temperature, solid-state degradation reactions proceed slowly and the peptide remains intact for extended periods. Repeated freeze-thaw cycles are best avoided because they promote aggregation and can shift the proportion of monomeric peptide present. Working aliquots are often prepared so that each portion is thawed only once, and desiccant is placed inside the vial to limit moisture uptake.
=== Files === Copying files: Making copies of files is the simplest and most common way to perform a backup. A means to perform this basic function is included in all backup software and all operating systems. Partial file copying: A backup may include only the blocks or bytes within a file that have changed in a given period of time. This can substantially reduce needed storage space, but requires higher sophistication to reconstruct files in a restore situation. Some implementations require integration with the source file system. Deleted files: To prevent the unintentional restoration of files that have been intentionally deleted, a record of the deletion must be kept. Versioning of files: Most backup applications, other than those that do only full only/System imaging, also back up files that have been modified since the last backup. "That way, you can retrieve many different versions of a given file, and if you delete it on your hard disk, you can still find it in your [information repository] archive."
Several small-scale studies involving 15 or fewer test subjects conducted in the 1950s and 1960s reported that adrenochrome triggered psychotic reactions such as thought disorder and derealization. In 1954, researchers Abram Hoffer and Humphry Osmond claimed that adrenochrome is a neurotoxic, psychotomimetic substance and may play a role in schizophrenia and other mental illnesses. In what Hoffer called the "adrenochrome hypothesis", he and Osmond in 1967 speculated that megadoses of vitamin C and niacin could cure schizophrenia by reducing brain adrenochrome. The treatment of schizophrenia with such potent anti-oxidants is controversial. In 1973, the American Psychiatric Association reported methodological flaws in Hoffer's work on niacin as a schizophrenia treatment and referred to follow-up studies that did not confirm any benefits of the treatment. Multiple additional studies in the United States, Canada, and Australia similarly failed to find benefits of megavitamin therapy to treat schizophrenia. The adrenochrome theory of schizophrenia waned, despite some evidence that it may be psychotomimetic, as adrenochrome was not detectable in people with schizophrenia. In the early 2000s, interest was renewed by the discovery that adrenochrome may be produced normally as an intermediate in the formation of neuromelanin. This finding may be significant because adrenochrome is detoxified at least partially by glutathione-S-transferase. Some studies have found genetic defects in the gene for this enzyme. Adrenochrome is also believed to have cardiotoxic properties.
After nylon's nationwide release in 1940, production was increased. 1300 tons of the fabric were produced during 1940. During their first year on the market, 64 million pairs of nylon stockings were sold. In 1941, a second plant was opened in Martinsville, Virginia, due to the success of the fabric.
Historically, American black bears occupied the majority of North America's forested regions. Today, they are primarily limited to sparsely settled, forested areas. American black bears currently inhabit much of their original Canadian range, though they seldom occur in the southern farmlands of Alberta, Saskatchewan and Manitoba; they have been extirpated on Prince Edward Island since 1937. Surveys taken in the mid-1990s found the Canadian black bear population to be between 396,000 and 476,000 in seven provinces; this estimate excludes populations in New Brunswick, the Northwest Territories, Nova Scotia and Saskatchewan. All provinces indicated stable populations of American black bears over the 2000s. The current range in the United States is constant throughout most of the Northeast and within the Appalachian Mountains almost continuously from Maine to northern Georgia, the northern Midwest, the Rocky Mountain region, the West Coast and Alaska. However, it becomes increasingly fragmented or absent in other regions. Despite this, American black bears in those areas seem to have expanded their range in recent decades, such as with sightings in Ohio, Illinois, southern Indiana, and western Nebraska. Sightings of itinerant black bears in the Driftless Area of southeastern Minnesota, northeastern Iowa, and southwestern Wisconsin are common.
The use of a drug of last resort may be based on agreement among members of a patient's care network, including physicians and healthcare professionals across multiple specialties, or on a patient's desire to pursue a particular course of treatment and a practitioner's willingness to administer that course. Certain situations such as severe bacterial related sepsis or septic shock can more commonly lead to last resorts. Therapies considered to be drugs of last resort may at times be used earlier, in the event that an agent would likely show the most immediate dose-response related efficacy in time-critical situations, such as high mortality circumstances. Many of the drugs considered last resorts fall into the categories of antibiotics, antivirals, and chemotherapy agents. These agents often exhibit what are considered to be among the most efficient dose-response related effects, or are drugs for which few or no resistant strains are known. When used for the teatment of infectious pathological disease, drugs of last resort are commonly withheld from administration until after the trial and failure of more commonly used treatment options, to prevent the development of drug resistance. One of the most commonly known examples of both antimicrobial resistance and the relationship to the classification of a drug of last resort is the emergence of Staphylococcus aureus (MRSA), sometimes also referred to as multiple-drug resistant S. aureus, due to resistance to non-penicillin antibiotics that some strains of S. aureus have shown to exhibit. In cases presenting with suspected S.
Sources: en.wikipedia.org
Cordelia goes to Alastair to gently break the news of Charles’ new engagement to him. Alastair already knew and is not happy when Cordelia tells him she eavesdropped on his recent conversation with Charles.
In an emergency, submarines can contact other ships to assist in rescue, and pick up the crew when they abandon ship. The crew can use escape sets such as the Submarine Escape Immersion Equipment to abandon the submarine via an escape trunk, which is a small airlock compartment that provides a route for crew to escape from a downed submarine at ambient pressure in small groups, while minimising the amount of water admitted to the submarine. The crew can avoid lung injury from over-expansion of air in the lungs due to the pressure change known as pulmonary barotrauma by maintaining an open airway and exhaling during the ascent. Following escape from a pressurized submarine, in which the air pressure is higher than atmospheric due to water ingress or other reasons, the crew is at risk of developing decompression sickness on return to surface pressure. An alternative escape means is via a deep-submergence rescue vehicle that can dock onto the disabled submarine, establish a seal around the escape hatch, and transfer personnel at the same pressure as the interior of the submarine. If the submarine has been pressurised the survivors can lock into a decompression chamber on the submarine rescue ship and transfer under pressure for safe surface decompression.
Protactinium exists in two major oxidation states: +4 and +5, both in solids and solutions; and the +3 and +2 states, which have been observed in some solids. As the electron configuration of the neutral atom is [Rn]5f26d17s2, the +5 oxidation state corresponds to the low-energy (and thus favored) 5f0 configuration. Both +4 and +5 states easily form hydroxides in water, with the predominant ions being Pa(OH)3+, Pa(OH)2+2, Pa(OH)+3, and Pa(OH)4, all of which are colorless. Other known protactinium ions include PaOF2+, PaOF+2, PaF−6, PaF2−7, PaF3−8, PaOSO+4, PaO(SO4)−2, PaO(SO4)3−3, PaOCl2−5, and PaCl−6.
=== Biology and medicine === Abductor digiti minimi muscle of hand Adrenomedullin, a vasodilator peptide hormone Acinar-to-ductal metaplasia, a condition affecting pancreatic cells (see Acinar cell § Acinar-to-ductal metaplasia)
Sources: en.wikipedia.org
Native GLP-1 is degraded within minutes by circulating enzymes. The synthetic version carries substitutions at positions that block enzymatic cleavage, plus a fatty acid side chain that promotes albumin binding. These two changes together extend circulation time from minutes to roughly a week.
Albumin binding keeps a large fraction of the compound in a slowly released reservoir within the bloodstream. Plasma levels decline gradually rather than falling sharply after each administration. That profile supports dosing intervals measured in days instead of hours.
The active peptide sequence is the same in both formats. The oral version adds an absorption enhancer that is not present in the injected solution. Differences in excipients and formulation affect uptake rather than the identity of the active molecule.
It is a glucagon-like peptide-1 receptor agonist, often grouped with the incretin mimetics. Its backbone is modified from the human hormone to resist enzymatic degradation and to bind albumin. These two features distinguish it from the native peptide.